Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: icosapent ethyl Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA + DHA in a SMEDS Formulation

NCT03443076
View directory record Official record
Conditions
Bioavailability
Interventions
EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved)
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 3 Interventional

Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression

NCT00096798
View directory record Official record
Conditions
Depressive Disorder, Depression
Interventions
Ethyl-eicosapentanoic acid (ethyl-EPA)
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Oct 18, 2026, 8:55 PM EDT
Withdrawn Phase 4 Interventional

A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid

NCT04811404
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ethyl Eicosapentaenoic Acid
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

NCT00001146
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Ethyl Eicosapentaenoic Acid, OmegaBrite
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

NCT00815685
View directory record Official record
Conditions
Cancer Cachexia
Interventions
Eicosapentaenoic Acid
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Fish Oil Study for High Triglyceride Levels in Children

NCT00915902
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Babu Balagopal
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Early Phase 1 Interventional

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
Other · Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Fish Oil in Lupus Patients

NCT00828178
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Omega-3, flow-mediated dilation of the brachial artery, corn starch
Drug · Device · Other
Lead sponsor
Michelle Petri M.D.,MPH
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Altering Lipids for Tolerance of Aromatase Inhibitor Therapy

NCT04268134
View directory record Official record
Conditions
Breast Cancer
Interventions
Omega-3 fatty acid supplement
Dietary Supplement
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

NCT02101970
View directory record Official record
Conditions
Breast Cancer
Interventions
Omega-3 Fatty Acids, Placebo Capsule, Diet and Exercise
Dietary Supplement · Other
Lead sponsor
Carol Fabian, MD
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 18, 2026, 8:55 PM EDT
Terminated Phase 3 Interventional Results available

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

NCT00944229
View directory record Official record
Conditions
Heart Failure
Interventions
LOVAZA (Omega-3), Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Acute Bioavailability of EPA and DHA From a DietarySupplement in Healthy Men and Women

NCT02865044
View directory record Official record
Conditions
Healthy
Interventions
Wax Ester Marine Oil, Ethyl Ester Marine Oil
Other
Lead sponsor
Calanus
Industry
Eligibility
18 Years to 59 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
Drug
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 18, 2026, 8:55 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

NCT05198843
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
Interventions
Dasatinib, Icosapent Ethyl
Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PRevention Using EPA Against coloREctal Cancer

NCT04216251
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Cancer, Endoscopic Surgery, Eicosapentaenoic Acid, Gastrointestinal Microbiome
Interventions
AMR101
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Results available

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

NCT00795717
View directory record Official record
Conditions
Cardiovascular Disease, HIV Infection
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
View directory record Official record
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

NCT00771914
View directory record Official record
Conditions
Increased Drug Resistance
Interventions
Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 18, 2026, 8:55 PM EDT
Withdrawn Phase 4 Interventional

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

NCT06280976
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Heart Attack
Interventions
Statin, Aspirin tablet, Nexlizet, LEQVIO, Vascepa, Jardiance, Colchicine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 18, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy Study of Stearidonic Acid (SDA) Soybean Oil-containing Foods on Red Blood Cell Fatty Acid Content

NCT01369550
View directory record Official record
Conditions
Healthy Volunteers, Markers of Cardiovascular Risk
Interventions
SDA soybean oil-containing foods, High-oleic sunflower oil containing foods, Eicosapentaenoic acid
Other
Lead sponsor
Monsanto Company, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 18, 2026, 8:55 PM EDT